Cetritin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cetritin

Property Description
Active Ingredient Cetirizine Hydrochloride
Form Tablet, Oral Solution
Pharmacological Class Second-Generation Antihistamine
General Purpose Relief of allergic symptoms
Origin Synthetic compound

What is Cetritin and Its Primary Classification?

Cetritin is a product containing the active pharmaceutical ingredient Cetirizine Hydrochloride, which is scientifically classified as a second-generation antihistamine. This class of drug works by specifically interfering with the body's natural allergic response pathways.

The pharmacological classification as a second-generation agent derives from its chemical structure as a synthetic compound within the family of piperazine derivatives. This design allows the drug to be highly selective for peripheral H1-receptors, minimizing its ability to cross the blood-brain barrier. This structure is associated with achieving effective symptom relief with a typically lower potential for causing notable sedation compared to older, less selective antihistamines. This characteristic positions it as an option for patients needing relief while maintaining daily function.

Composition, Origin, and Available Forms

The medication is a single-ingredient product, containing only the active compound Cetirizine Hydrochloride along with essential excipients. Chemically, Cetirizine is the carboxylic acid metabolite of Hydroxyzine. The compound exhibits rapid absorption following administration.

For administration, Cetirizine is widely available as an oral medication, manufactured in common dosage forms such as a solid tablet and a liquid oral solution. This ensures the delivery of the drug via the oral route across different patient needs, including pediatric patient groups who may utilize the liquid form.

General Purpose and Mechanism Summary

The general purpose of this medication is to achieve symptom relief during instances like seasonal pollen exposure or contact with environmental triggers. Cetirizine accomplishes this by engaging in histamine antagonism, a process where the drug acts as a specific H1-receptor antagonist.

By blocking these receptors, the drug prevents histamine—the substance released by the body during an allergy—from binding to cells that initiate allergic physical manifestations. This mechanism of action results in the reduction of discomfort caused by the immune response, such as itching and swelling.

Regulatory References

  1. MedlinePlus

What side effects are possible with Cetritin?

Possible Side Effects and Safety Information

Cetritin's safety profile is officially classified by regulatory bodies into standardized frequency categories reflecting observations from clinical use and surveillance. The most frequently documented effects are classified as Common, affecting Nervous System Disorders and Gastro-intestinal Disorders. These Common adverse reactions typically include somnolence (drowsiness), headache, dry mouth, and fatigue. Other reactions, such as agitation, nausea, and rash, are classified as Uncommon.

Serious Adverse Reactions and Systemic Effects

Certain adverse reactions are documented as Rare or Very Rare but are considered clinically significant. Rare serious effects listed in official labeling include Hypersensitivity and Convulsions. Very Rare reactions include Anaphylactic Shock, Angioneurotic oedema (Angioedema), and reports of abnormal hepatic function. The documented effects span several System-Organ Classes, including the Immune system disorders, Hepatobiliary disorders, and Renal and urinary disorders (e.g., dysuria, enuresis).

Safety Considerations and Restrictions

Official safety statements address specific populations and contextual use. Caution is recommended for patients with pre-existing renal impairment or liver disease, as drug clearance may be reduced. Similarly, caution is advised for patients with neurological risks, such as those prone to convulsions, or individuals with predisposing factors for urinary retention. Furthermore, official documentation notes a specific Time-Related Safety Pattern: intense pruritus (itching) or urticaria has been observed upon discontinuation of the medicine, particularly after long-term use. This medication is also noted to inhibit the response to allergy skin tests.

Overdose and Emergency Response

Overdose and When to Seek Help

If you suspect an overdose, seek immediate emergency medical attention.

Documented Overdose Profile

Overdose cases are officially characterized by central nervous system (CNS) effects, particularly when a single high dose (such as 50 mg or more) has been ingested. The most frequently reported signs and symptoms associated with an acute overdose include somnolence (drowsiness), restlessness, and irritability.

Other documented clinical manifestations of overdose may affect multiple body systems and can include:

  • Cardiovascular: Tachycardia (fast heart rate)
  • CNS: Headache, confusion, dizziness, fatigue, tremor, stupor, malaise
  • Ocular: Mydriasis (dilated pupils)
  • Gastrointestinal: Diarrhea
  • Renal/Urinary: Urinary retention

In children, initial symptoms of overdose may first present as restlessness and irritability before progressing to drowsiness.

Emergency Response

There is no specific antidote for this medication. Therefore, the management of an overdose requires immediate, supportive, and symptomatic treatment under continuous medical supervision. If a large amount has been recently ingested, a healthcare provider may consider measures to prevent further absorption of the drug, such as administering activated charcoal or performing gastric lavage. The drug is not effectively removed from the body by dialysis.

Therapeutic Uses of Cetritin

Therapeutic Indications

Cetritin is a second-generation antihistamine used primarily to manage symptoms associated with allergic conditions. It functions by blocking the action of histamine, a substance in the body that causes allergic reactions.

Allergic Rhinitis

Cetritin is used for the relief of nasal and ocular symptoms associated with allergic rhinitis. This includes both seasonal allergic rhinitis, commonly known as hay fever, and perennial allergic rhinitis, which occurs year-round due to indoor allergens. Targeted symptoms include:

  • Sneezing: Reduction in the frequency and intensity of sneezing fits.
  • Rhinorrhea: Management of a runny or discharge-heavy nose.
  • Nasal Congestion: Relief from the feeling of a blocked or stuffy nose.
  • Nasal Pruritus: Alleviation of itching sensations within the nasal passages.
  • Ocular Symptoms: Relief from red, itchy, and watery eyes often associated with pollen or pet dander exposure.

Chronic Idiopathic Urticaria

In addition to respiratory allergies, Cetritin is utilized in the treatment of chronic idiopathic urticaria. This condition is characterized by the spontaneous appearance of wheals (hives) and swelling on the skin over a period of six weeks or more without a known cause. The benefits in this context include:

  • Reduction of Wheals: Decrease in the number and size of hives.
  • Pruritus Relief: Significant reduction in the intense itching associated with skin outbreaks.
  • Improved Skin Comfort: Management of the localized inflammation and redness.

Mechanism of Action and Benefits

As a selective H1-receptor antagonist, Cetritin offers specific therapeutic advantages for patients seeking symptom management:

  • Selectivity: It specifically targets peripheral H1 receptors, which minimizes its impact on the central nervous system compared to first-generation antihistamines.
  • Duration of Effect: The pharmacological profile allows for a sustained effect, typically providing symptom coverage for a 24-hour period.
  • Consistency: It helps maintain a stable baseline of relief for individuals exposed to consistent environmental allergens.

Eligibility and Restrictions for Use

Official Eligibility Profile for Cetritin (Cetirizine Hydrochloride)

Cetritin's eligibility profile is strictly defined by regulatory documents, governing who is permitted to use the medicine under official labeling.

Absolute Contraindications

Use of Cetritin is prohibited for patients with known hypersensitivity to the active substance, cetirizine, its parent compound hydroxyzine, or any piperazine derivatives. It is also contraindicated in patients with severe renal impairment, defined as a Creatinine Clearance le 10 mL/min. For the tablet formulation, use is prohibited in children under six years of age.

Age-Group Eligibility

The medicine is approved for adults and adolescents ge 12 years of age. It is also approved for children ge 6 months of age, with the minimum age depending on the formulation. Use in older adults is permitted, but caution is advised due to the higher likelihood of reduced renal function.

Restricted and Conditional Use

Patients with moderate renal impairment (CrCl 30–49 mL/min) are eligible but require a restricted dose. Use during pregnancy and lactation requires caution as the substance is excreted into human milk. Caution is also advised for epileptic patients or those with risk factors for urinary retention.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cetritin (Cetirizine Hydrochloride) has officially documented interaction patterns based on both pharmacodynamic and pharmacokinetic effects, as noted in government regulatory labeling. No combinations are explicitly listed as strictly contraindicated due to drug-drug interaction risk.

Documented Pharmacodynamic and Substance Interactions

Concurrent use with alcohol (ethanol) or other Central Nervous System (CNS) depressants (such as sedatives or tranquilizers) is associated with the potential for an additive reduction in alertness and additional impairment of CNS performance.

Documented Pharmacokinetic Interactions

A specific pharmacokinetic interaction is documented with Theophylline when administered at 400 mg once daily. This co-administration results in a 16% decrease in the clearance of Cetirizine, though the clearance of Theophylline itself is not altered. Studies examining co-administration with other substances, including Azithromycin, Erythromycin, Ketoconazole, and Pseudoephedrine, have shown no observed interactions.

Administration and Population Notes

The presence of food causes a delay in the rate of absorption of Cetirizine (prolonging T max) but does not affect the total extent of absorption (AUC). Regulatory documents also note that Cetirizine's clearance is decreased in patients with renal impairment and in geriatric populations, often due to age-related diminished renal function.

Mechanism of Action

Selective Blockade of Peripheral H1-Receptors

The mechanism is centered on the competitive antagonism of the Histamine H1-receptor located predominantly on peripheral cells, such as vascular endothelial cells and nerve endings. By binding to these receptors, Cetirizine functionally suppresses the signaling cascade initiated by the endogenous mediator histamine. This action targets the core biological process of the immediate hypersensitivity reaction, which results in the modulation of the signal that normally triggers increased vascular permeability.


Vascular and Cellular Pathway Modulation

Beyond the initial receptor blockade, the drug's mechanism is associated with modulating the late-phase response by influencing inflammatory cells. This includes inhibiting the movement and activation of cells like eosinophils into reaction sites. This secondary cellular effect is associated with the modulation of pathways involved in sustained inflammatory processes, which influences the duration and extent of histamine-mediated cellular changes.


Mechanistic Basis of Limited Central Activity

The chemical structure of Cetirizine imparts low lipophilicity, which restricts its ability to cross the blood-brain barrier (BBB). This mechanical constraint ensures that the selective H1-receptor blockade is concentrated in the periphery, thereby excluding substantial interference with central nervous system (CNS) H1-receptors. This functional selectivity contributes to the drug's peripheral physiological profile.

Dosage and Administration Information

Official Administration Guidelines

The usage of Cetritin (Cetirizine Hydrochloride) is defined by standard prescribing information to ensure proper administration, addressing the route, dose, and frequency. The drug is most commonly available for oral intake as 5 mg and 10 mg tablets or an oral solution; however, it is also approved for intravenous (IV) administration as an injectable solution and as an ophthalmic solution for local use.

Standard Dosing and Frequency

The standard adult and adolescent regimen (12 years and older) is 10 mg once daily, which is also the maximum dose allowed in a 24-hour period. An alternative starting dose of 5 mg once daily may be used for less severe symptoms. The medication may be taken with or without food as the extent of absorption is not significantly altered, although the rate of absorption might be delayed.

Age Group Standard Oral Regimen Key Administration Rule
Adults (12 yrs and older) 10 mg once daily Maximum dose is 10 mg per 24 hours.
Children 6–11 yrs 5 mg twice daily or 10 mg once daily Tablets are generally not appropriate for children under 6.
IV Administration 10 mg once every 24 hours Must be administered as an IV push over 1 to 2 minutes.

Dose Modification for Specific Populations

Dosage adjustment is explicitly required in patients with reduced kidney function. For individuals with moderate impairment, the dose is typically reduced to 5 mg once daily. In cases of severe renal impairment, the dose is further reduced to 5 mg once every two days to align with established instructions. The liquid forms require precise measurement using the designated dosing device to ensure the correct amount is administered, particularly for pediatric patients.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials: Measures Related to Pain

The core research, primarily conducted in multi-center, placebo-controlled Phase III trials, evaluated the effects of the study drug on indices related to moderate-to-severe pain. The primary endpoint for these trials was the change in patient-reported pain scores (using the VAS scale) over a 12-week period.

  • Key Finding: Initial studies suggested a numerical difference in the change in pain scores was observed between the study drug group and the placebo group.
  • Dosing Regimens: Different dosing schedules (once vs. twice daily) were compared. Research investigated differences in measured responses when the compound was studied under different consistent dosing regimens.

Investigational Research: Markers of Inflammation

Further laboratory and preliminary clinical research focused on outcomes related to specific markers of inflammation.

  • Combination Therapy: Studies examined whether the combined treatment (study drug plus a standard care agent) was associated with changes in the inflammatory markers C-Reactive Protein (CRP) and Interleukin-6 (IL-6) in specific patient cohorts. Findings were heterogeneous across different inflammatory disorders.
  • Timing of Action: Research investigated the timing of action; its action was compared to that of older therapies in relation to inflammatory markers. This investigation was conducted using surrogate markers and a non-standardized time frame.

Important Disclaimer

The evidence presented here strictly summarizes the findings and methods of published research and clinical trials concerning the investigational drug.

Please note that these studies do not replace the need for professional medical consultation. Decisions about treatment must be made by a qualified healthcare provider based on a full review of an individual's specific medical condition and circumstances.

Frequently Asked Questions (FAQ)

Common questions about Cetritin (FAQ)


Q: How quickly does Cetritin typically start to work?

A: Official product information indicates that the effects of Cetritin generally begin relatively quickly following an oral dose. Regulatory studies suggest that relief starts within approximately thirty minutes, with the maximum effect often occurring around one hour after the dose.

Q: What is the expected duration of effect for a dose of Cetritin?

A: Cetritin is typically recommended for once-daily use. According to regulatory documents, the drug's effects are described as generally lasting for approximately 24 hours, which is consistent with its typical once-daily recommendation.

Q: Do children use a different form or strength of Cetritin than adults?

A: Yes, regulatory documents specify different dosage regimens for various pediatric age groups. For example, official documentation states that the tablet formulation is generally not approved for use in children under six years old, and different formulations are available to accommodate varying dosing needs.

Q: Can Cetritin be used during allergy seasons that last several months?

A: According to official guidelines, Cetritin is indicated for the daily treatment of chronic conditions like perennial allergic rhinitis and chronic hives. The duration of use described in regulatory documents is generally dependent upon the type and ongoing nature of the condition being addressed.

Q: Is it typical for Cetritin to take several days to reach its full effect?

A: Official information indicates that consistent amounts of the medicine in the body, known as steady-state, are typically reached within three days of regular daily use. This is when the concentration of the drug is stable.

Q: What is the recommended period of time a person should generally use Cetritin?

A: Official labeling clarifies that the period of use is generally dependent upon the specific type, duration, and course of the allergic condition being managed. It is not associated with a single, fixed duration for all users.

Q: What is the general difference between Cetritin and similar older allergy medicines?

A: Cetritin is classified as a second-generation antihistamine. This design is associated with a lower potential for causing notable sedation compared to some older, first-generation allergy medicines because its action is more concentrated outside of the central nervous system.

Q: Are there any widely known non-prescription medicines that can interact with Cetritin?

A: Regulatory warnings describe a potential for interaction with other non-prescription medicines that cause drowsiness, such as other antihistamines or certain sleep aids. Combining these products is associated with the potential for an additive reduction in alertness and an increased risk of side effects like drowsiness.

Q: Can Cetritin be taken at the same time as cold and flu relief medicines?

A: Many cold and flu relief products contain ingredients that can act as Central Nervous System (CNS) depressants. Official safety information includes a warning that combining these types of medicines is associated with an increased potential for side effects such as excessive drowsiness or reduced performance.

Q: Can Cetritin be taken with herbal supplements?

A: Official patient information includes a warning about potential issues when taking Cetritin alongside certain herbal supplements. This warning applies specifically to supplements that are known to cause similar side effects, such as sleepiness, dry mouth, or difficulty with urination.

Q: Does Cetritin affect blood pressure in a noticeable way?

A: Cetritin by itself is generally described as having minimal cardiovascular effects. However, if the product is a combination medicine that includes a decongestant, the decongestant component is associated with effects on blood pressure.

Q: What happens if a person misses a dose of Cetritin?

A: Official guidance describes taking the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the guidance is to skip the missed dose and continue with the regular schedule.

Q: Is Cetritin used for treating symptoms of the common cold?

A: The approved indications for Cetritin, as listed in regulatory documentation, are for the relief of symptoms related to allergies, such as hay fever and chronic hives. The medication is not approved for the treatment of the common cold.

Q: Can people who are lactose intolerant use the tablet form of Cetritin?

A: Regulatory documentation indicates that the tablet formulation contains lactose monohydrate as an excipient. Official warnings describe that the tablet form may not be suitable for individuals with certain inherited sugar intolerances, such as total lactase deficiency.

Q: Are there any specific laboratory tests that can be affected by taking Cetritin?

A: Official safety information notes that Cetritin is known to interfere with the results of allergy skin tests. The official documentation notes that a temporary cessation of the medication, often referred to as a wash-out period, is necessary before these tests are performed to avoid inaccurate results.

Q: Is it okay to take Cetritin at night instead of in the morning?

A: Official administration instructions indicate that the once-daily dose can be taken at a regular time, either in the morning or the evening. This flexibility is provided in patient information leaflets.

Q: Does Cetritin have a known effect on weight?

A: According to adverse reaction data included in some regulatory documents, increased appetite has been reported as an adverse event associated with the use of the drug.

Q: What official information exists regarding Cetritin and driving or operating machinery?

A: Official labeling includes a warning stating that caution is necessary when driving a vehicle or operating potentially dangerous machinery because the medication has the potential to cause drowsiness (somnolence) in some individuals.

How should Cetritin be stored and disposed of?

Storage and Disposal Conditions for Cetritin

Official labeling mandates specific conditions to maintain the stability of Cetirizine Hydrochloride.


️ Storage Requirements

The medication must be stored at Controlled Room Temperature, typically between 20 C and 25 C. Storage must avoid excessive heat above 40 C and be protected from light and high humidity.

Safety and Handling

It is required to keep the product out of the sight and reach of children and to not use it if the original container's safety seal is broken.

️ Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste. Regulatory advice suggests avoiding disposal of medicines via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cetritin found in:

A-Z Index: